Stefano Rivella, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, comments on the potential of combining the TGF-β ligand trap RAP-GRL with an iron restriction therapy called TMPRSS6-ASO, which targets the matriptase-2 (TMPRSS6) gene using antisense oligonucleotides (ASO). Dr Rivella explains that the combination of these two drugs with different mechanisms of action helps improve anemia and normalize iron metabolism. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.